Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1497 of 6351
-
MRNA technology takes on autoimmune diseases in new trial
Disease control Not yet recruitingAutoimmune diseases, such as immune thrombocytopenia (ITP), immune hemolytic anemia (AIHA), systemic lupus erythematosus (SLE), lupus nephritis (LN), idiopathic inflammatory myopathy (IIM), ulcerative colitis (UC), and systemic sclerosis (SSc), are a type of chronic disabling dis…
Early phase 1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Liver cirrhosis patients: new drug may cut rebleeding risk
Disease control By invitation onlyCirrhosis is a serious liver disease where scar tissue replaces healthy liver tissue, often leading to portal hypertension-a condition where blood pressure in the liver's blood vessels rises. A life-threatening complication of this is variceal bleeding, which happens when swollen…
Phase 4 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
MRNA therapy hopes to fix copper problem in wilson disease
Disease control Recruiting nowThis study adopted an open, single-arm, non-randomized, dose-escalation research design, aiming to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetic and immunogenicity characteristics of single and multiple intravenous infusions of DSL101 in patients with W…
Early phase 1 • Sponsor: DSciLab Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can red light save your sight? new trial for severe nearsightedness
Disease control Recruiting nowThe goal of this clinical trial is to learn if LED repeated low-level red light (RLRL) therapy works to treat pathologic myopia in adults. It will also learn about the safety of LED-RLRL. The main questions it aims to answer are: Does LED-RLRL modulate choroidal microcirculation…
Sponsor: Shanghai Eye Disease Prevention and Treatment Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Virus cocktail takes on superbugs in cystic fibrosis trial
Disease control Not yet recruitingThis is a Phase 1, open-label, multi-center pilot study evaluating the safety and microbiological activity of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics in adults with cystic fibrosis (CF) experiencing pulmonary exacerbations due to antibio…
Phase 1 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New injection shows promise for kidney disease in early trial
Disease control Recruiting nowTo investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Could a common mineral ease teen depression? new trial investigates
Symptom relief Recruiting nowThe purpose of this study is to investigate the role and mechanisms of selenium in depression among children and adolescents, aiming to provide new insights for understanding the pathogenesis and treatment of depression in this population.
Phase 2 • Sponsor: First Affiliated Hospital of Chongqing Medical University • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo aims to improve colorectal cancer treatment
Disease control Not yet recruitingThe standard second-line treatment for metastatic colorectal cancer (mCRC) involves chemotherapy (FOLFOX or FOLFIRI) combined with an antiangiogenic agent, such as bevacizumab or aflibercept. Maintaining VEGF inhibition between first and second-line treatments has shown modest cl…
Phase 2 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 26, 2026 14:57 UTC
-
Fat cell therapy shows promise for stiff hands in scleroderma
Symptom relief Recruiting nowThis prospective, randomized, blinded, multicenter clinical study aims to evaluate the safety and efficacy of autologous adipose-derived regenerative cells (ADRCs) in improving hand dysfunction in patients with systemic sclerosis (SSc). The study plans to enroll 48 eligible patie…
Sponsor: Cytori Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Could your own probiotics ease bowel troubles after rectal cancer surgery?
Symptom relief Not yet recruitingRectal cancer patients who received low anterior resection combined with ileostomy may effectively reduce the probability of anastomotic leakage after surgery. However, due to the long-term semi-abandoned state of the distal colon, the probability of bowel dysfunction after ileos…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Could less immunotherapy be better? new trial tests Every-6-Week dosing for tough breast cancer
Disease control Recruiting nowTriple-negative breast cancer (TNBC), defined by the lack of ER, PR and HER2 expression, is refractory to endocrine therapy and anti-HER2 agents. Chemotherapy was once the mainstay for advanced TNBC, but its limited efficacy necessitates optimized therapeutic strategies. TNBC's h…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could a histamine shot tame chronic hives?
Disease control Recruiting nowThis is a prospective, multicentre, non-interventional, observational, real-world evidence (RWE) study designed to evaluate the effectiveness and safety of Immunoglobulin/Histamine Complex (IHC) in patients with Chronic Urticaria in India.
Sponsor: Bharat Serums and Vaccines Limited • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug ZGGS34 targets Hard-to-Treat cancers
Disease control Recruiting nowThis is a multicenter, open-label Phase 1/2 study in participants with advanced solid tumors. The study consists of two parts: Part 1 is a dose-escalation phase to evaluate the safety and tolerability of ZGGS34 in advanced solid tumor participants; Part 2 is a cohort-expansion ph…
Phase 1/2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New pill could replace needles for anemia in dialysis patients
Disease control Not yet recruitingThis study is to evaluate the efficacy and safety of QLG1218(daprodustat) following a switch from erythropoiesis-stimulating agent (ESA) in Chinese HD subjects with renal anemia who are currently treated with ESA. The primary objective is to demonstrate non-inferiority of QLG1218…
Phase 3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New shot for eczema shows promise in Mid-Stage trial
Disease control Recruiting nowThis is a multi-center, randomized, double-blind, parallel, placebo-controlled phase 2 clinical study. A total of 403 adult participants with moderate to severe AD are planned to be enrolled to evaluate efficacy, safety, PK characteristics, immunogenicity, and changes in PD chara…
Phase 2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can a chemo drug keep sarcoma at bay? new trial aims to find out
Disease control Recruiting nowMaintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)
Phase 2 • Sponsor: National Health Research Institutes, Taiwan • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy aims to shrink Hard-to-Treat tumors
Disease control Not yet recruitingThe goal of this Phase Ib/II interventional study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of QLC5513 combined with QL1706± platinum in the treatment of patients with advanced or metastatic malignant solid tumors. This study is divided into two phase…
Phase 1/2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for Crohn's patients: study tests guselkumab after ustekinumab fails
Disease control Recruiting nowThe purpose of this study is to evaluate how well guselkumab works in participants with Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.
Phase 4 • Sponsor: Xian-Janssen Pharmaceutical Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo aims to stop rare lymphoma from coming back after transplant
Disease control Not yet recruitingAllogeneic hematopoietic stem cell transplantation is an important treatment method for NK-T cell lymphoma, but the recurrence rate after transplantation is relatively high. Therefore, exploring efficient and low-toxicity maintenance treatment strategies after transplantation is …
Phase 2 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New school program aims to tackle myopia, obesity, and mental health in one go
Prevention Not yet recruitingThis study aims to develop and evaluate a scalable, hybrid intervention model for the co-prevention of myopia, obesity, and mental health issues among children. By integrating cognitive behavioral therapy principles, the model targets key modifiable lifestyle factors-including di…
Sponsor: Fangbiao Tao • Aim: Prevention
Last updated Jun 27, 2026 08:06 UTC